Skip to main content
. 2016 Jul 8;7(32):51535–51552. doi: 10.18632/oncotarget.10493

Table 2. IC50 (μM) of HepG2 and U87 MG cells treatment by different formulations (n = 4).

Cell lines Taxol® PALA PALA-ME PALA-sLDL
HepG2 0.0131 ± 0.0059 0.131 ± 0.023 0.319 ± 0.042 0.424 ± 0.111
U87 MG 1.14 ± 0.29 1.67 ± 0.28 4.98 ± 0.64 1.28 ± 0.17